COCP SEC Filings: 8-K, 10-Q, S-3 & 424B – Cocrystal Pharma

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Norovirus Challenge Study of CDI-988

Sep 9, 2026

8-K

Cocrystal Pharma, Inc. Appoints Carol L. Brosgart to Board of Directors

Aug 18, 2026

8-K

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Aug 17, 2026

8-K

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Aug 3, 2026

8-K

Cocrystal Pharma, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jul 17, 2026

8-K

Cocrystal Pharma, Inc. Appoints James Sapirstein as Chief Executive Officer

Jun 9, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 5,736,773 | Warrants amount: 5,736,773 |

Sep 29, 2025

424B5

REGISTERED OFFERING

Sep 15, 2025

424B3

UPDATED | ATM

Sep 12, 2025

424B5

ATM | Offering amount: $7,250,000 | Float: 7,744,500

Jun 15, 2023

424B5

SHELF OFFERING | Shares amount: 26,000,000 | Share price: $1.54 | Offering amount: $40,040,000.00

May 5, 2021

424B5

SHELF OFFERING | Shares amount: 14,285,715 | Share price: $1.05 | Offering amount: $15,000,001.00 | Bank: H.C. Wainwright & Co.

Aug 27, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-3

April 2026 SHELF

Apr 23, 2026

S-1

SHARE RESALE REGISTRATION

Sep 19, 2025

S-3/A

SHELF | ATM | Offering amount: $150,000,000.00 | Float: 7,744,500 EFFECTIVE

May 24, 2023

S-3

SHELF | ATM | Offering amount: $150,000,000.00 | Float: 7,744,500 EFFECTIVE

May 12, 2023

S-3/A

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

May 4, 2020

S-3

Form S-3 - Registration statement under Securities Act of 1933

Apr 17, 2020

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 27, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 5, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 5, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 7, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D/A

OPKO HEALTH, INC. (Filed by)

Nov 6, 2026

Brosgart Carol L (Reporting)

Aug 21, 2026

SCHEDULE 13D

OPKO HEALTH, INC. (Filed by)

Aug 7, 2026

SCHEDULE 13D/A

FROST PHILLIP MD ET AL (Filed by)

Aug 7, 2026

FROST PHILLIP MD ET AL (Reporting)

Aug 6, 2026

FROST PHILLIP MD ET AL (Reporting)

Aug 5, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 4, 2026

CORRESP

Form CORRESP - Correspondence

Apr 29, 2026

LETTER

Form UPLOAD - SEC-generated letter

Apr 28, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 26, 2025

CORRESP

Form CORRESP - Correspondence

Sep 25, 2025

LETTER

Form UPLOAD - SEC-generated letter

Sep 24, 2025

Cocrystal Pharma, Inc. COCP · SEC Filings